Drug
Insulin Degludec
Insulin Degludec: highest development phase Phase 3, developed by Novo Nordisk. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| insulin degludec NCT02034513 | Phase 3 | Diabetes |
| insulin degludec NCT01664247 | Phase 3 | Diabetes |
| insulin degludec NCT01865331 | Phase 1 | Diabetes |
| insulin degludec NCT00964964 | Phase 1 | Diabetes |
Latest
No recent events.
Follow Insulin Degludec on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.